Sector News

Novartis’s Alcon eye-care unit to enter Swiss index after spin off

February 6, 2019
Life sciences

Get involved in the discussion! Click here to comment on this story

Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland’s 20 largest listed companies, market operator SIX said on Tuesday.

Information about any other changes to SMI and Switzerland’s other indexes will be released later, the bourse said.

Novartis last year announced the spin off of Alcon to the Basel drugmaker’s shareholders in the first half of this year.

Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.

By John Revill

Source: Reuters

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 18, 2019

Bristol-Myers’ $74B Celgene buy wins antitrust nod in FTC party-line split vote

Life sciences

LinkedIn Twitter FacebookIndustry watchers largely expected that Bristol-Myers Squibb and Celgene would win U.S. antitrust clearance for their $74 billion merger. But what’s perhaps unexpected is that the permission was […]

November 18, 2019

Novartis pivots Shanghai R&D site from early discovery to development

Life sciences

LinkedIn Twitter FacebookNovartis is calling it curtains on early drug discovery at its R&D site in Shanghai in a companywide move to “rebalance” its discovery and early development efforts. The […]

November 15, 2019

Merck builds in CNS diseases with $576m Calporta buy

Life sciences

LinkedIn Twitter FacebookMerck & Co has had mixed fortunes in neurological diseases of late, but remains committed to the category and has just bolstered its early-stage pipeline with a $576 […]

Subscribe to our Weekly Newsletter

We're easy to reach